tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

PRNAF Stock Latest News

Alterity Therapeutics price target raised to $12 from $8 at Maxim
The FlyAlterity Therapeutics price target raised to $12 from $8 at Maxim
22h ago
ATHE
Alterity Therapeutics announces ATH434 Phase 2 trial results
PremiumThe Fly
Alterity Therapeutics announces ATH434 Phase 2 trial results
1d ago
ATHE
Alterity Therapeutics Reports Promising Phase 2 Results for MSA Drug ATH434
PremiumCompany Announcements
Alterity Therapeutics Reports Promising Phase 2 Results for MSA Drug ATH434
2d ago
Alterity Therapeutics Initiates Trading Halt Pending Phase II Trial Results
PremiumCompany Announcements
Alterity Therapeutics Initiates Trading Halt Pending Phase II Trial Results
4d ago
Alterity Therapeutics Ltd (ADR) trading halted, news pending
PremiumThe Fly
Alterity Therapeutics Ltd (ADR) trading halted, news pending
4d ago
ATHE
Alterity Therapeutics reports cash balance of A$4.54M as of December 31
PremiumThe FlyAlterity Therapeutics reports cash balance of A$4.54M as of December 31
7d ago
ATHE
Alterity Therapeutics Advances ATH434 Clinical Trials with Promising Data
Premium
Company Announcements
Alterity Therapeutics Advances ATH434 Clinical Trials with Promising Data
7d ago
Alterity Therapeutics Highlights Key Milestones in Neurodegenerative Disease Pipeline
Premium
Company Announcements
Alterity Therapeutics Highlights Key Milestones in Neurodegenerative Disease Pipeline
14d ago
Alterity CEO says ‘filled with optimism for 2025’
PremiumThe Fly
Alterity CEO says ‘filled with optimism for 2025’
22d ago
ATHE
Alterity Therapeutics Director Acquires Additional Options
PremiumCompany Announcements
Alterity Therapeutics Director Acquires Additional Options
25d ago
Alterity Therapeutics Issues 170M Unlisted Options
PremiumCompany Announcements
Alterity Therapeutics Issues 170M Unlisted Options
1M ago
Alterity Therapeutics initiated with a Buy at Maxim
PremiumThe Fly
Alterity Therapeutics initiated with a Buy at Maxim
2M ago
ATHE
Alterity Therapeutics completes last patient visit in ATH434-201 trial
PremiumThe FlyAlterity Therapeutics completes last patient visit in ATH434-201 trial
2M ago
ATHE
Alterity Therapeutics Advances with ATH434 Trial Completion
Premium
Company Announcements
Alterity Therapeutics Advances with ATH434 Trial Completion
2M ago
Alterity Therapeutics Advances Amid Successful AGM
Premium
Company Announcements
Alterity Therapeutics Advances Amid Successful AGM
2M ago
Alterity Therapeutics Alerts Investors on Potential Risks
PremiumCompany Announcements
Alterity Therapeutics Alerts Investors on Potential Risks
2M ago
Alterity Therapeutics Advances in Neurodegenerative Drug Trials
PremiumCompany Announcements
Alterity Therapeutics Advances in Neurodegenerative Drug Trials
2M ago
Alterity Therapeutics appoints Abby Macnish Niven as secretary
PremiumThe Fly
Alterity Therapeutics appoints Abby Macnish Niven as secretary
2M ago
ATHE
Alterity Therapeutics Appoints New Company Secretary
PremiumCompany Announcements
Alterity Therapeutics Appoints New Company Secretary
2M ago
Alterity Therapeutics announces presentation on bioMUSE study
PremiumThe FlyAlterity Therapeutics announces presentation on bioMUSE study
3M ago
ATHE
Alterity Therapeutics Unveils New Advances for MSA Tracking
Premium
Company Announcements
Alterity Therapeutics Unveils New Advances for MSA Tracking
3M ago
Alterity Therapeutics announces new publication on ATH434
Premium
The Fly
Alterity Therapeutics announces new publication on ATH434
3M ago
ATHE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >